【摘要】 目的探讨重组人血管内皮抑制素与化疗药物(奥沙利铂+替吉奥胶囊)联合治疗晚期胃癌的有效性和安全性。方法 21例二线复治的晚期胃癌患者接受重组人血管内皮抑制素联合化疗药物治疗,化疗后评价疗效和毒性。结果全组21例共完成治疗周期86个,获得完全缓解(CR)1例,部分缓解(PR)8例,稳定(SD)7例,病情进展(PD)5例,有效率(PR)42.9%,生活质量(QOL)改善率76.2%。主要毒副反应包括骨髓抑制和消化道反应,未见明显心血管系统毒性和出血情况。结论重组人血管内皮抑制素联合化疗治疗晚期胃癌患者具有较好疗效,不增加化疗毒性,耐受性好,值得临床推广应用。更多还原

【Abstract】 Objective To study the efficacy and safety of recombinant human endostatin(Oxaliplatin+Gio capsules)combined treatment in advanced gastric cancer.Methods Twenty-one cases of second-line retreatment of advanced gastric cancer patients received recombinant human endostatin combined with chemotherapy drugs.The efficacy and toxicity after chemotherapy were evaluated.Results All 21 patients completed a total of 86 treatment cycles,among which,there was 1 case of CR,8 cases of PR,7 cases of SD,and 5 cases of PD.PR was 42.9%,and QOL improvement rate was 76.2%.Main side effects included bone marrow suppression and gastrointestinal reactions and there were no significant cardiovascular toxicity and bleeding.Conclusion Recombinant human endostatin combined with chemotherapy for advanced gastric cancer patients has a good effect.It does not increase the toxicity of chemotherapy and it is well tolerated.Therefore it is worthy of clinical application.更多还原